Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Method for preparing radionuclide-labeled chelating agent-ligand complexes

Patent ·
OSTI ID:872538

Radionuclide-labeled chelating agent-ligand complexes that are useful in medical diagnosis or therapy are prepared by reacting a radionuclide, such as .sup.90 Y or .sup.111 In, with a polyfunctional chelating agent to form a radionuclide chelate that is electrically neutral; purifying the chelate by anion exchange chromatography; and reacting the purified chelate with a targeting molecule, such as a monoclonal antibody, to form the complex.

Research Organization:
University of California
DOE Contract Number:
FG03-84ER60233
Assignee:
Regents of University of California (Oakland, CA)
Patent Number(s):
US 5958374
OSTI ID:
872538
Country of Publication:
United States
Language:
English

References (17)

Technetium labeling of monoclonal antibodies with functionalized BATOs. 1. TcCl(DMG)3PITC [phenyl isothiocyanate]. journal May 1991
Synthesis of C- and N-functionalised derivatives of 1,4,7-triazacyclononane-1,4,7-triyltriacetic acid (NOTA), 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetrayltetra-acetic acid (DOTA), and diethylenenetriaminepenta-acetic acid (DTPA): bifunctional complexing agents for the derivatisation of antibodies journal January 1990
A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent journal March 1992
Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies: Radionuclide selection and dose calculations for labeled antibodies journal September 1984
Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates journal January 1991
Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates journal July 1993
Tumour targeting with radiolabelled macrocycle–antibody conjugates journal January 1990
The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex journal August 1988
Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. journal August 1992
Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N',N'',N''',N''''-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-N,N',N'',N''',N'''',N'''''-hexaacetic acid journal March 1991
Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions journal October 1984
The production of 99mTc-labeled conjugated antibodies using a cyclam-based bifunctional chelating agent journal January 1987
[47] A centrifuged-column procedure for the measurement of ligand binding by beef heart F1 book January 1979
Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development
  • DeNardo, Sally J.; Peng, Jo-Sen B.; DeNardo, Gerald L.
  • International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, Vol. 13, Issue 4 https://doi.org/10.1016/0883-2897(86)90002-4
journal January 1986
Kinetics of interaction of metal ions with two tetraazatetraacetate macrocycles journal September 1982
Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent journal July 1985
Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. journal June 1988